About This Item
Product Name
MILLIPLEX® Human Circulating Cancer Biomarker Panel,
description
Configurable Human Circulating Cancer Biomarker 10-Plex Panel 4
species reactivity
human
packaging
pkg of 1 ea
manufacturer/tradename
Milliplex®
assay range
inter-assay cv: <10%
intra-assay cv: <20%, accuracy: 80-110%, standard curve range: 0.1-100 ng/mL
(L1CAM), standard curve range: 0.1-100 ng/mL
(Mesothelin), standard curve range: 0.3-250 ng/mL
(Hepsin), standard curve range: 1.4-1,000 ng/mL
(CD44), standard curve range: 1.4-1,000 ng/mL
(Transglutaminase 2 (TGM2)), standard curve range: 13.7-10,000 pg/mL
(EpCAM), standard curve range: 13.7-10,000 pg/mL
(Midkine), standard curve range: 2.7-2,000 ng/mL
(ALDH1A1), standard curve range: 20.6-15,000 pg/mL
(Carbonic Anhydrase IX (CA9)), standard curve range: 27.4-20,000 pg/mL
(Kallekrein-6)
technique(s)
multiplexing: suitable
input
cell culture supernatant(s)
plasma
detection method
fluorometric (Luminex® xMAP® technology)
shipped in
wet ice
storage temp.
2-8°C
General description
Application
Analytes included: Aldheyde dehydrogenase 1 Family, Member A1 (ALDH1A1), Carbonic Anhydrase IX (CA9), CD44, Epithelial cell adhesion molecule (EpCAM), Hepsin, Kallikrein-6, Mesothelin, Midkine, Neural cell adhesion Molecule L1 (L1CAM), Transglutaminase 2 (TGM2)
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Features and Benefits
- Versatile 10-Plex Analyte Kit: This panel allows for the simultaneous quantification of ten significant biomarkers, including ALDH1A1, CA9, and CD44, providing a broad scope for cancer research.
- Diverse Sample Compatibility: Suitable for human serum, plasma, and tissue culture supernatants, allowing flexibility in sample types for various research applications.
- Recommended Sample Dilution: The assay suggests using 25 μL of 1:5 diluted serum or plasma, with tissue culture supernatants requiring appropriate dilution, simplifying the preparation process.
- Comprehensive Insights into Tumor Dynamics: By enabling the simultaneous measurement of multiple circulating biomarkers, this panel aids researchers in exploring the complex interactions between tumors and their microenvironment.
- Increased Efficiency in Research: The multiplex capability allows for a significant boost in sample throughput, enabling researchers to analyze a larger number of samples in less time, which is crucial for high-volume research.
Legal Information
Disclaimer
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Still not finding the right product?
Explore all of our products under MILLIPLEX® Human Circulating Cancer Biomarker Panel
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
target_organs
Respiratory Tract
Storage Class
6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
wgk
WGK 3
Regulatory Information
This item has
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.